What is Ultrasight?
Based in Rehovot, Israel, Ultrasight operates at the intersection of artificial intelligence and point-of-care diagnostics. The company provides a sophisticated software platform designed to pair seamlessly with handheld ultrasound devices. This technological synergy enables non-expert clinicians to perform high-quality cardiac sonography, effectively bridging the gap in diagnostic accessibility. By facilitating accurate, real-time cardiac assessments, Ultrasight is fundamentally transforming the standard of care for patients in diverse clinical environments, ranging from remote primary care settings to high-acuity hospital wards.
How much funding has Ultrasight raised?
Ultrasight has raised a total of $15M across 2 funding rounds:
Series A
$2M
Series B
$13M
Series A (2019): $2M with participation from Yozma Group
Series B (2021): $13M led by Yozma Group Korea, Weizmann Institute of Science, and Atain Specialty Insurance Company
Key Investors in Ultrasight
Yozma Group Korea
A prominent venture capital firm focused on fostering cross-border innovation and supporting high-growth technology startups.
Weizmann Institute of Science
A world-renowned multidisciplinary research institution that actively supports the commercialization of breakthrough scientific discoveries.
Atain Specialty Insurance Company
A specialized insurance provider that engages in strategic investments within the healthcare and technology sectors to drive industry innovation.
What's next for Ultrasight?
With the recent infusion of capital, Ultrasight is poised to scale its operational footprint and deepen its market penetration. The company's strategic roadmap likely involves expanding its regulatory approvals across international markets and enhancing its proprietary diagnostic algorithms. As the healthcare industry continues to prioritize decentralized care models, Ultrasight's ability to provide enterprise-grade cardiac imaging via portable hardware positions it as a critical player in the future of digital health. Investors are closely monitoring the firm's ability to integrate its software into existing hospital workflows, which remains a key indicator of long-term commercial viability and clinical adoption.
See full Ultrasight company page
